Flow of US biotech VC dol­lars on track to match record 2018 lev­els — Chi­na? Not so much

With the third quar­ter of the year be­hind us, the US pri­vate biotech ecosys­tem has some sol­id num­bers to cel­e­brate — and some fog to clear out as it looks out the glob­al win­dow.

While the over­all vol­ume of deals and their sizes may not sur­pass red hot 2018 lev­els, Pitch­Book an­a­lysts see the deal count on pace to match the record, eas­i­ly tow­er­ing over the nine years pri­or. An ef­fer­ves­cent IPO mar­ket and sev­er­al high pro­file ac­qui­si­tions helped keep en­thu­si­asm high; in fact, this has been the most lu­cra­tive year for over­all VC ex­its in a decade, the da­ta com­pa­ny and the Na­tion­al Ven­ture Cap­i­tal As­so­ci­a­tion not­ed in their quar­ter­ly Ven­ture Mon­i­tor re­port pub­lished Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER